The Comprehensive Tirzepatide FAQ

Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) in multiple jurisdictions including Australia. It is administered as a once-weekly subcutaneous injection. The peptide activates two hormonal pathways simultaneously, providing synergistic metabolic effects.

Tirzepatide has been extensively studied in clinical trials demonstrating efficacy for both glycaemic control and weight loss. Real-world use and post-marketing safety monitoring continue to characterise long-term outcomes.

How does tirzepatide work? Tirzepatide activates GIP and GLP-1 receptors on cells throughout the body, triggering cascades that enhance insulin secretion, suppress glucagon, slow gastric emptying, and promote appetite suppression. These overlapping effects create comprehensive metabolic benefit. How much weight loss can I expect? Clinical trials documented weight loss ranging from approximately 12-22% of baseline body weight depending on dose, with average weight loss at the highest dose approximately 21-22%. Individual responses vary. Can tirzepatide improve my HbA1c? Yes, tirzepatide reduces HbA1c by approximately 1.5-2.1 percentage points depending on baseline glycaemic status and dose. This improvement translates to better long-term glycaemic control and reduced diabetes complications. Does tirzepatide work better than semaglutide? For weight loss, yes—tirzepatide achieves approximately 8 percentage points greater weight loss than semaglutide in comparable trials. For HbA1c, tirzepatide provides approximately 0.3-0.4 percentage point greater reduction. Both are effective; tirzepatide is more potent.

What are the most common side effects? Gastrointestinal effects (nausea, vomiting, diarrhoea, constipation) are most common, occurring in 20-50% of recipients depending on specific effect and dose. Most are mild-to-moderate and transient, improving within 4-12 weeks. Is tirzepatide safe long-term? Clinical trial data demonstrate good safety over 52-104 weeks. Very long-term safety (beyond 3-5 years) is still being characterised through ongoing follow-up. Can I take tirzepatide if I have other health conditions? Tirzepatide is generally suitable for most individuals with type 2 diabetes or obesity. However, individuals with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should avoid tirzepatide. Severe kidney or liver disease may require caution. Consult your healthcare provider about your specific situation. What if I stop taking tirzepatide? Weight loss often regains partially if tirzepatide is discontinued, as appetite signalling returns toward baseline. However, the degree of regain varies. Benefits are sustained if lifestyle modifications established during therapy are maintained. Is tirzepatide approved in Australia? Yes. Mounjaro (type 2 diabetes) and Zepbound (weight management) are both TGA-approved and available in Australia through prescriptions. Availability through the PBS depends on clinical criteria and individual circumstances.

Very long-term efficacy and safety beyond 3-5 years are still being characterised. Cardiovascular outcome trials are ongoing and will clarify whether tirzepatide reduces major cardiovascular events. Metabolic adaptations over extended treatment periods—whether efficacy plateaus or declines—require further study. Individual predictors of who will respond best to tirzepatide and how to optimise tolerability in non-responders require additional research. Efficacy and safety in populations excluded from clinical trials (very elderly, severe kidney disease, pregnant individuals) require future investigation. These knowledge gaps will be addressed through continued follow-up of trial cohorts and accumulation of real-world experience.